Actelion Pharmaceuticals US, Inc. drugs

6 results

  • opsumit

    (macitentan)
    Actelion Pharmaceuticals US, Inc.
    OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.

  • tracleer

    (bosentan)
    Actelion Pharmaceuticals US, Inc.
    TRACLEER is indicated for treating pulmonary arterial hypertension (PAH) in adults to improve exercise ability and reduce clinical worsening. It is also indicated for pediatric patients aged 3 and older to improve pulmonary vascular resistance (PVR) in cases of idiopathic or congenital PAH.

  • uptravi

    (Selexipag)
    Actelion Pharmaceuticals US, Inc.
    UPTRAVI is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce hospitalization risk. Its efficacy was demonstrated in a long-term study involving patients with WHO Functional Class II–III PAH symptoms, including idiopathic, heritable, and connective tissue disease-related PAH.

  • veletri

    (epoprostenol)
    Actelion Pharmaceuticals US, Inc.
    VELETRI is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity, primarily in patients with NYHA Functional Class III–IV symptoms, including idiopathic or heritable PAH and PAH linked to connective tissue diseases.

  • ventavis

    (iloprost)
    Actelion Pharmaceuticals US, Inc.
    VENTAVIS is indicated for treating pulmonary arterial hypertension (PAH) in WHO Group 1 patients, aiming to improve exercise tolerance, symptoms, and prevent deterioration. It is primarily studied in patients with NYHA Functional Class III–IV symptoms, including idiopathic/heritable PAH and PAH linked to connective tissue diseases.

  • zavesca

    (miglustat)
    Actelion Pharmaceuticals US, Inc.
    ZAVESCA is indicated as monotherapy for treating adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.